Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status.

被引：0
|
作者：
Park, Se Jun
Lee, Myung Ah
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[2] Catholic Univ Korea, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
405
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Park, Se Jun
    Kim, Hyunho
    Shin, Kabsoo
    Lee, Myung Ah
    Hong, Tae Ho
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (11) : 1021 - 1030
  • [2] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Se Jun Park
    Hyunho Kim
    Kabsoo Shin
    Myung Ah Lee
    Tae Ho Hong
    World Journal of Gastrointestinal Oncology, 2019, (11) : 1021 - 1030
  • [3] Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Tschoep-Lechner, Katharina Elisabeth
    Milani, Valeria
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf-Dieter
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2013, 29 (01) : 8 - 16
  • [4] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer : Is There a Standard?
    Almhanna, Khaldoun
    Kim, Richard
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1176 - 1183
  • [5] GEMCITABINE AND CISPLATIN COMBINED WITH REGIONAL HYPERTHERMIA AS SECOND-LINE TREATMENT IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER
    Lechner, Katharina
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf
    ANNALS OF ONCOLOGY, 2012, 23 : 62 - 62
  • [6] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Maeda, Shimpei
    Motoi, Fuyuhiko
    Onogawa, Tohru
    Morikawa, Takanori
    Shigeru, Ottomo
    Sakata, Naoaki
    Takadate, Tatsuyuki
    Naitoh, Takeshi
    Rikiyama, Toshiki
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) : 539 - 545
  • [7] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Shimpei Maeda
    Fuyuhiko Motoi
    Tohru Onogawa
    Takanori Morikawa
    Ottomo Shigeru
    Naoaki Sakata
    Tatsuyuki Takadate
    Takeshi Naitoh
    Toshiki Rikiyama
    Yu Katayose
    Shinichi Egawa
    Michiaki Unno
    International Journal of Clinical Oncology, 2011, 16
  • [8] Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
    Lee, Jeung Eun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    Bang, Seungmin
    GUT AND LIVER, 2020, 14 (01) : 135 - 143
  • [9] A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1
    Morizane, Chigusa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (12) : 973 - 973
  • [10] Analysis of efficacy and prognostic factors for second-line chemotherapy in gemcitabine-refractory advanced biliary tract cancer
    Okano, N.
    Kawai, K.
    Kobayashi, T.
    Naruge, D.
    Nagashima, F.
    Furuse, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345